Cannabinoids, a group of C21 compounds present in Cannabis sativa L.. Their carboxylic acids, analogs and transformation products are the active ingredients found in hasish and marihuana. (-)-trans-D9-tetrahydrocannabinol (D9-THC) is the major psychopharmacologically active component of cannabis. Cannabis affect cognition and memory, euphoria and sedation, and antinociception (analgesia) without the respiratory depression problems associated with opioid analgesics. D9-THC is also immunosuppressive. It impairs cell-mediated immunity, humoral immunity and cellular defenses against a variety of infectious agents both in vivo and in vitro. To date, two subtypes of the G-protein coupled cannabinoid receptor, CB1 and CB2, have been identified. The first brain-derived endogenous cannabinoids, an unsaturated fatty-acid ethanolamide, arachidonylethanolamide (AEA, also called anandamide) was found in brain. AEA has higher affinity for the CB1 than for the CB2. CB1 (rat/mouse 473aa, human 472aa, ~95% sequence homology) has 7 TM domains with an extracellular N-terminus and cytoplasmic C-terminus. An alternative spliced N-terminal variant, CB1A, has also been reported. The CB1 receptor has been shown to inhibit adenylate cyclase activity in a pertussis-toxin sensitive manner and to be more responsive to psychoactive cannabinoids than to non-psychoactive cannabinoids. CB1 couples to a pertussis-toxin sensitive G-protein to regulate Ca2+ currents, to activate inward rectifying K+ channels and to activate MAP Kinases. CB1 receptor is distributed throughout the brain, with higher representation in the hippocampus, a brain region essential for storage of newly acquired information and changes of mood and behavioral state. In the cerebellum, CB1 is most dense in the molecular layer, consistent with the effects of cannabinoids on the coordination of motor function and motor learning. Outside the CNS, CB1 expression is found in testes, endothelial cells and ileum longitudinal smooth muscle.

Suitable for use in ELISA and Antibody Blocking. Not suitable for use in Western Blot due to low molecular weight. Other applications not tested.

Antibody Blocking: Use 5-10ug per 1ug of affinity purified antibody (C1075-71) or 1ul of antiserum (C1075-71F). ELISA: 50-100ng control peptide per well. Optimal dilutions to be determined by the researcher.

Lyophilized powder is stable for at least 12 months at -20°C Reconstituted product must be stored in aliquots at -20°C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer.

Highly Purified

~1mg/ml

Supplied as a lyophilized powder in PBS, pH 7.5, 0.05% sodium azide.

This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications without the expressed written authorization of United States Biological.